Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. - Stupp, R.; Tosoni, A.; Bromberg, J. E. C.; Hau, P.; Campone, M.; Gijtenbeek, J.; Frenay, M.; Breimer, L.; Wiesinger, H.; Allgeier, A.; van den Bent, M. J.; Bogdahn, U.; et al. (Annals of Oncology, 2011)